Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Ascorbate-Meglumine Therapeutic for SRS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03927625
Recruitment Status : Withdrawn (IRB determination)
First Posted : April 25, 2019
Last Update Posted : January 19, 2021
Sponsor:
Collaborator:
Duke University
Information provided by (Responsible Party):
Chris Lascola, MD, Duke University

Brief Summary:
Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine as a Novel Magnetic Resonance Imaging-guided Adjunctive Therapeutic for Stereotactic Radiosurgery (SRS).

Condition or disease Intervention/treatment Phase
Safety Drug: Ascorbate-Meglumine Phase 1

Detailed Description:

Phase 1, single-center, open-label study in subjects receiving SRS for brain metastases.

The study will consist of 4 principal cohorts (n=3 in each cohort). Each cohort will receive an escalating dose of ascorbate-meglumine as an MRI-detectable adjunctive therapeutic to SRS.

Subjects will complete a planning MRI for SRS with gadolinium- diethylenetriamine penta-acetic acid (GD-DPTA) per standard of care for SRS. Forty-eight hours after the planning MRI, the subjects will complete the study MRI with ascorbate-meglumine contrast agent. Each cohort will receive an escalating dose of ascorbate-meglumine by intravenous administration over 1 hour during the MRI. The total dose of ascorbate-meglumine-will escalate from the first cohort to the next cohort in a sequential manner. During ascorbate-meglumine infusion, MRI scans will be performed to evaluate the contrast effect and PK blood draws will occur at defined time points.

Patients will return for the SRS procedure within 1 week following the planning MRI per standard of care. During SRS, subjects will receive a second dose of ascorbate-meglumine as an adjunctive therapeutic.

Patients will enter into a follow up phase within 2 weeks after the SRS procedure per standard of care.

The primary endpoint is to evaluate the safety of parenteral ascorbate-meglumine as a MRI-detectable adjunctive therapeutic to SRS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: dose escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine as a Novel Magnetic Resonance Imaging-guided Adjunctive Therapeutic for Stereotactic Radiosurgery
Estimated Study Start Date : December 1, 2021
Estimated Primary Completion Date : August 1, 2024
Estimated Study Completion Date : August 1, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Meglumine

Arm Intervention/treatment
Experimental: Cohort 1
Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.16 g/min for 60 minutes.
Drug: Ascorbate-Meglumine
Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate, 125 mM ascorbic acid and 125 mM meglumine in sterile water for injection.
Other Name: Vitamin C

Experimental: Cohort 2
Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The first cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.31 g/min for 60 minutes.
Drug: Ascorbate-Meglumine
Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate, 125 mM ascorbic acid and 125 mM meglumine in sterile water for injection.
Other Name: Vitamin C

Experimental: Cohort 3
Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The second cohort of patients will receive ascorbate-meglumine at a dose administration rate of 0.63 g/min for 60 minutes.
Drug: Ascorbate-Meglumine
Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate, 125 mM ascorbic acid and 125 mM meglumine in sterile water for injection.
Other Name: Vitamin C

Experimental: Cohort 4
Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases The third cohort of patients will receive ascorbate-meglumine at a dose administration rate of 1.25 g/min for 60 minutes.
Drug: Ascorbate-Meglumine
Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate, 125 mM ascorbic acid and 125 mM meglumine in sterile water for injection.
Other Name: Vitamin C




Primary Outcome Measures :
  1. Safety, as measured by adverse events [ Time Frame: 1 week after receiving study drug with SRS ]
    Adverse events will be monitored in patients receiving ascorbate formulated with meglumine during the SRS procedure



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Capable of giving written informed consent to participate in the study before undergoing any screening procedures
  2. Age greater than (>) 18
  3. Life expectancy of at least 3 months
  4. GPA score 0.5 or greater
  5. A contrast-enhanced brain MRI scan performed within 2 weeks of study registration
  6. Imaging demonstrates the presence of 1 to 3 intact (not previously irradiated or resected) brain metastases
  7. Maximum tumor diameter ≤ 3 cm for the largest lesion

Exclusion Criteria:

  1. Primary lesion with radiosensitive histology (i.e., small cell carcinoma, germ-cell tumors, lymphoma, leukemia, and multiple myeloma)
  2. Metastases in the brain stem, pons or medulla or within 3 mm of optic apparatus (such that some portion of the optic nerve or chiasm would receive >10Gy)
  3. Previous whole-brain radiation (previous SRS to or surgical resection of other brain metastases is permitted if more than 3 months prior to the date of enrollment on this protocol.)
  4. Pregnancy
  5. History or manifestation of glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency
  6. History of oxalate kidney stones
  7. History of iron overload or hemochromatosis
  8. History of allergy to ascorbic acid
  9. Anuria, dehydration, severe pulmonary congestion or pulmonary edema or fixed low cardiac input since all are conditions for which osmotic diuresis are contraindicated and ascorbic acid has high osmolarity
  10. Subjects who are on the following drugs and cannot have a drug substitution: flecainide, methadone, amphetamines, quinidine, and chlorpropamide; note: high dose ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs.
  11. Subjects who are on strong inducers, inhibitors or substrates of CYP within 3 days of planned administration of study ascorbate-meglumine.
  12. Patients for which MRI is contra-indicated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03927625


Locations
Layout table for location information
United States, North Carolina
Duke Cancer Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Chris Lascola, MD
Duke University
Investigators
Layout table for investigator information
Principal Investigator: John Kirkpatrick, M.D. Ph.D. Duke University Health System
Layout table for additonal information
Responsible Party: Chris Lascola, MD, Associate Professor of Radiology, Duke University
ClinicalTrials.gov Identifier: NCT03927625    
Other Study ID Numbers: Pro00103610
First Posted: April 25, 2019    Key Record Dates
Last Update Posted: January 19, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No